Lorlatinib, also known as Lorbrena, is a novel targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). As a potent inhibitor of the ALK protein, lorlatinib has demonstrated remarkable efficacy in patients who have not responded to other ALK inhibitors. This article aims...